T Cell Lymphoma Clinical Trial
Official title:
A Phase II Single Arm Proof of Concept, Safety, Efficacy, Multicenter Study of Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplant in CD30 Expressing Peripheral T Cell Lymphomas
For participants with CD30 positive Mature T-cell lymphomas who have received brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A-CHP) as induction (4 to 6 cycles) and achieved complete response (CR) or chemo-sensitive partial response (PR) and deemed suitable for autologous stem cell transplant (ASCT) as consolidation, the investigators propose to add brentuximab vedotin after ASCT. There is currently no standard of care treatment to prevent relapse after upfront treatment or ASCT for CD30-positive peripheral T-cell lymphoma's (PTCL)s. An agent that could improve outcomes in this population would be a major contribution to the field and is likely to be practice changing. Therefore, in addition to studying the anti-lymphoma activity of A-CHP as induction therapy, for participants who respond to induction the investigators propose to add brentuximab vedotin consolidation after ASCT in participants treated with consolidative upfront ASCT.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04653649 -
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06420076 -
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
|
Phase 1/Phase 2 | |
| Completed |
NCT01561833 -
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
|
Phase 1 | |
| Recruiting |
NCT05367856 -
Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00798096 -
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03770000 -
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05996185 -
Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT01430013 -
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT04502446 -
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
|
Phase 1 | |
| Terminated |
NCT04973527 -
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
|
Phase 1 | |
| Recruiting |
NCT05230680 -
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03672084 -
Allo-HSCT as First-line Consolidation in High-risk PTCL
|
||
| Recruiting |
NCT05852028 -
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
|
||
| Enrolling by invitation |
NCT03628612 -
Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified
|
Phase 2 | |
| Recruiting |
NCT00974324 -
Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00877656 -
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05772728 -
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)
|
N/A | |
| Completed |
NCT01300026 -
AMG 319 Lymphoid Malignancy FIH
|
Phase 1 | |
| Terminated |
NCT00880867 -
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04840875 -
Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma
|
Phase 1 |